These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25661298)

  • 21. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
    Thompson IM; Chi C; Ankerst DP; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Natl Cancer Inst; 2006 Aug; 98(16):1128-33. PubMed ID: 16912265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The uncertain relationship between obesity and prostate cancer: an Italian biopsy cohort analysis.
    De Nunzio C; Freedland SJ; Miano L; Finazzi Agrò E; Bañez L; Tubaro A
    Eur J Surg Oncol; 2011 Dec; 37(12):1025-9. PubMed ID: 21963050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of obesity on tumour volume in patients with prostate cancer.
    Capitanio U; Suardi N; Briganti A; Gallina A; Abdollah F; Lughezzani G; Salonia A; Freschi M; Montorsi F
    BJU Int; 2012 Mar; 109(5):678-84. PubMed ID: 21777363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml.
    Loeb S; Roehl KA; Nadler RB; Yu X; Catalona WJ
    J Urol; 2007 Dec; 178(6):2348-52; discussion 2352-3. PubMed ID: 17936844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
    Andriole GL; Marberger M; Roehrborn CG
    J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
    Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS
    J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study.
    Vidal AC; Howard LE; Moreira DM; Castro-Santamaria R; Andriole GL; Freedland SJ
    Clin Cancer Res; 2015 Feb; 21(4):756-62. PubMed ID: 25520389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
    Culp S; Porter M
    BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of diabetes mellitus on high-grade prostate cancer detection among Japanese obese patients with prostate-specific antigen less than 10 ng/mL.
    Fukushima H; Masuda H; Kawakami S; Ito M; Sakura M; Numao N; Koga F; Saito K; Fujii Y; Yamamoto S; Yonese J; Fukui I; Kihara K
    Urology; 2012 Jun; 79(6):1329-34. PubMed ID: 22656412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic.
    Price MM; Hamilton RJ; Robertson CN; Butts MC; Freedland SJ
    Urology; 2008 May; 71(5):787-91. PubMed ID: 18267334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB.
    Bittner N; Merrick GS; Andreini H; Taubenslag W; Allen ZA; Butler WM; Anderson RL; Adamovich E; Wallner KE
    Urology; 2009 Jul; 74(1):171-6. PubMed ID: 19232691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baseline Prostate Atrophy is Associated with Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy.
    Moreira DM; Bostwick DG; Andriole GL; Peterson BL; Cohen HJ; Castro-Santamaria R; Freedland SJ
    J Urol; 2015 Nov; 194(5):1241-6. PubMed ID: 26165588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
    Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
    J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Body mass index as a predictor of prostate cancer: development versus detection on biopsy.
    Freedland SJ; Terris MK; Platz EA; Presti JC
    Urology; 2005 Jul; 66(1):108-13. PubMed ID: 15992911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Body mass index and prostate cancer severity: do obese men harbor more aggressive disease on prostate biopsy?
    Chamie K; Oberfoell S; Kwan L; Labo J; Wei JT; Litwin MS
    Urology; 2013 May; 81(5):949-55. PubMed ID: 23477756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Body mass index trends and role of obesity in predicting outcome after radical prostatectomy.
    Motamedinia P; Korets R; Spencer BA; Benson MC; McKiernan JM
    Urology; 2008 Nov; 72(5):1106-10. PubMed ID: 18602142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
    Bokhorst LP; Zhu X; Bul M; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1654-60. PubMed ID: 23043563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy.
    Eggener SE; Roehl KA; Catalona WJ
    J Urol; 2005 Aug; 174(2):500-4. PubMed ID: 16006880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.